Pfizer CEO Ian Read also says a potential U.S. tax holiday would be only a temporary solution.» Read More
The AMA's new recognition of obesity as a "disease" could put a dent into insurers' bottom lines—at least in the short-term—but boost profits for makers of weight-loss drugs.
The American Medical Association says obesity should be classified as a disease. CNBC's Bertha Coombs reports AMA's Patrice Harris says the hope is for doctors to be more proactive in treating obese patients.
Small business owners are already curtailing hiring because of concerns over the cost of Obamacare, a recent survey found.
With the Dow up more than 2000 points for the year, Jim Cramer thinks now is a good time to single out stocks that haven’t rallied, but soon could.
Already sluggish health-care inflation is projected to slow down even more in 2014 as consumers, employers and the federal government continue looking to cut medical costs, a new report said Tuesday.
Months before Americans buy coverage under Obamacare, it's becoming clear that choices for millions of people will vary depending on where they live. The NYT reports.
A Supreme Court decision gives the FTC the go-ahead to continue suing drug makers over deals that delay generic versions from being sold.
The Supreme Court says deals between pharmaceutical companies and their generic drug competitors can sometimes be illegal.
Jim Cramer believes this company is about to create immense value with the stroke of a pen.
Dawn Zier, President & CEO of Nutrisystem, discusses her company's plans to set up programs designed to meet the needs of people with special dietary needs, and its expansion into selling its products in Wal-Mart.
Biotech and drug companies say the benefits of genome research are on the way, and just as importantly, advances are pushing the technology toward affordability.
A unanimous Supreme Court decision barred patents on naturally occurring DNA, but analysts said the ruling did little harm to biotech companies.
Like many of the 2,200-plus people who showed up for a 5:30 a.m. dental clinic last month, Patty Kennedy knows that bad teeth translate into poor employment prospects.
Cyclicals are heating up as the summer approaches and the economy starts to show signs of improvement, analysts say.
GlaxoSmithKline fired the head of its R&D operations in China after a tipster spurred an inquiry that found "misrepresented" data were used in a multiple sclerosis study.
Obama administration to scrap age restrictions on the sale of morning-after pills, making the emergency contraception available to women and girls of any age without a prescription.
Obamacare's implementation may look like a "train wreck," but Universal Health Services CEO Alan Miller says his $7 billion hospital company is well-positioned for the changes.
Months after the Komen Foundation's decision to cut Planned Parenthood funding sparked widespread backlash, the group's CEO still holds her position and received a large raise.
Transplant experts will meet to decide whether and how to change the rules for children, after the parents of two youngsters successfully sued to get restrictions temporarily lifted.
AstraZeneca is to buy U.S. respiratory drug specialist Pearl Therapeutics for up to $1.15 billion, as Britain's second biggest drugmaker steps up a drive to rebuild its product pipeline via deal-making.
Get the best of CNBC in your inbox